Trial results

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

NCT06691243 on ClinicalTrials.gov · last registry update 2026-09-10

A small phase 2 — 40 participants, against a typical 115. Due to report January 2027, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Safety of semaglutide in patients with cocaine use disorder (CUD) with and without HIV. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 2 times since then.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

University of Maryland, Baltimore

Sponsor type

Other

Enrollment

40

Started

2025-08-07

Primary completion

2027-01 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Safety of semaglutide in patients with cocaine use disorder (CUD) with and without HIV

Conditions studied

Cocaine Use Disorder · HIV

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.